T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Funko
FNKO
$335M
| $281K | ﹤0.01% |
14,934
-414
| -3% | -$7.34K |
|
|
FFAI
2602
Faraday Future Intelligent Electric
FFAI
$12M
| – | – |
0
| – | – |
|
2603
Harmony Biosciences
HRMY
$2.24B
| $280K | ﹤0.01% |
+6,565
| New | +$262K |
|
|
HIND
2604
Vyome Holdings
HIND
$15.2M
| $280K | ﹤0.01% |
+1
| New | +$679K |
|
|
PTRA
2605
DELISTED
Proterra Inc. Common Stock
PTRA
| $280K | ﹤0.01% |
+31,700
| New | +$325K |
|
|
GAN
2606
DELISTED
GAN Ltd
GAN
| $279K | ﹤0.01% |
+30,355
| New | +$371K |
|
2607
NRC Health Common Stock
NRC
$471M
| $279K | ﹤0.01% |
6,725
-240
| -3% | -$10.4K |
|
2608
Seaboard Corp
SEB
$4.08B
| $279K | ﹤0.01% |
71
-3
| -4% | -$11.9K |
|
2609
Bally's
BALY
$660M
| $278K | ﹤0.01% |
7,310
-865,912
| -99% | -$37.9M |
|
2610
Rush Street Interactive
RSI
$2.85B
| $278K | ﹤0.01% |
+16,829
| New | +$317K |
|
|
VBIV
2611
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $278K | ﹤0.01% |
3,955
+253
| +7% | +$21.3K |
|
|
CSII
2612
DELISTED
Cardiovascular Systems, Inc.
CSII
| $278K | ﹤0.01% |
14,790
-623
| -4% | -$16.6K |
|
|
SGFY
2613
DELISTED
Signify Health, Inc.
SGFY
| $278K | ﹤0.01% |
+19,538
| New | +$302K |
|
|
GNOG
2614
DELISTED
Golden Nugget Online Gaming, Inc. Class A Common Stock
GNOG
| $278K | ﹤0.01% |
+27,898
| New | +$395K |
|
2615
Inogen
INGN
$154M
| $277K | ﹤0.01% |
8,142
+1,055
| +15% | +$38.3K |
|
2616
Angi Inc
ANGI
$196M
| $276K | ﹤0.01% |
+3,000
| New | +$325K |
|
2617
Vaxcyte
PCVX
$8.76B
| $276K | ﹤0.01% |
11,581
-800
| -6% | -$18.6K |
|
2618
Asure Software
ASUR
$251M
| $275K | ﹤0.01% |
35,080
-2,900
| -8% | -$25.4K |
|
2619
Anika Therapeutics
ANIK
$283M
| $274K | ﹤0.01% |
7,659
+435
| +6% | +$17.4K |
|
2620
Heron Therapeutics
HRTX
$63.5M
| $274K | ﹤0.01% |
29,995
-23,400
| -44% | -$239K |
|
2621
Haverty Furniture Companies
HVT
$450M
| $274K | ﹤0.01% |
8,972
-2,557
| -22% | -$82.4K |
|
2622
ACM Research
ACMR
$5.65B
| $273K | ﹤0.01% |
9,600
| – | – |
|
2623
Evolus
EOLS
$530M
| $272K | ﹤0.01% |
41,745
+18,300
| +78% | +$126K |
|
|
AVID
2624
DELISTED
Avid Technology Inc
AVID
| $272K | ﹤0.01% |
8,349
-580
| -6% | -$18.1K |
|
2625
BCE
BCE
$21.7B
| $271K | ﹤0.01% |
5,200
-4
| -0.1% | -$204 |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.